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Abstract
Background: The Education Thérapeutique des patients Insuffisants Cardiaques (ETIC; Therapeutic Education for
Patients with Cardiac Failure) trial aimed to determine whether a pragmatic education intervention in general
practice could improve the quality of life of patients with chronic heart failure (CHF) compared with routine care.
Results: This cluster randomised controlled clinical trial included 241 patients with CHF attending
54 general practitioners (GPs) in France and involved 19 months of follow-up. The GPs in the Intervention Group
were trained during a 2-day interactive workshop to provide a patient education programme. The mean age of the
patients was 74 years (±10.5), 62 % were men and their mean left-ventricular ejection fraction was 49.3 % (± 14.3).
At the end of the follow-up period, the mean Minnesota Living with Heart Failure Questionnaire scores in the
Intervention and Control Groups were 33.4 (± 22.1) versus 27.2 (± 23.3; P = 0.74, intra-cluster coefficient [ICC] = 0.11).
At the end of the follow-up period, the 36-Item Short Form Health Survey (mental health and physical health)
scores in the Intervention and Control Groups were 58 (± 22.1) versus 58.7 (± 23.9; P = 0.58, ICC = 0.01) and 52.8
(± 23.8) versus 51.6 (± 25.5; P = 0.57, ICC = 0.01), respectively.
Conclusions: Patient education delivered by GPs to elderly patients with stable heart failure in the ETIC programme
did not achieve an improvement in their quality of life compared with routine care. Further research on improving
the quality of life and clinical outcomes of elderly patients with CHF in primary care is necessary.
Trial registration: The Education Thérapeutique des patients Insuffisants Cardiaques (ETIC; Therapeutic Education
for Patients with Cardiac Failure) trial is a cluster randomised controlled trial registered with ClinicalTrials.gov
(Registration Number: NCT01065142) and the French Drug Agency (Agence Nationale de Sécurité du Médicament
et des Produits de Santé; Registration Number: 2009-A01142-55).
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Background
Chronic heart failure (CHF) is a common condition that
is increasing in prevalence with the ageing of the popu-
lation and with improvements in the management of
acute and chronic heart disease, especially ischaemic car-
diomyopathies [1]. The prevalence of CHF in French
general practice is estimated to be about 10 % for pa-
tients aged over 59 years [2]. The European Society of
Cardiology guidelines recommend medical and elec-
trical management to reduce morbidity and mortality
and improve quality of life. They also recommend
non-pharmacological management including self-care
management, patient education, and self-care behav-
iour to improve patients’ adherence to treatment and
quality of life [3].
In France, patient education programmes delivered by
multidisciplinary teams in outpatient clinics attached to
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hospitals have been assessed for their impact on rehospi-
talisation, mortality and participation rates in patients
with heart failure (HF) [4, 5]. However, this does not re-
flect the situation of the majority of patients, most of
whom are ambulatory and cared for by general practi-
tioners (GPs). Only a few studies have assessed the effect
of HF management programmes delivered in the pri-
mary care setting [6–10]. Others recruited patients in
primary care but the intervention was delivered by prac-
tice nurses or doctors’ assistants [11–13]. However, these
studies do not reflect the ‘real-life’ situation of primary
care in France, where practice nurses are rare at GP
clinics. Therefore, more evidence is needed on the effect
of patient education programmes delivered by GPs. As
GPs are the doctors closest to patients, we hypothesised
that a patient education delivered by them could im-
prove the quality of life of patients with HF.
The Education Thérapeutique des patients Insuffisants
Cardiaques (ETIC; Therapeutic Education for Patients
with Cardiac Failure) trial was designed to assess
whether a pragmatic educational programme for patients
with CHF delivered by trained GPs could improve the
quality of life of patients with CHF compared with rou-
tine care.
Methods
Study design and randomisation
The study design has been published previously [14].
The ETIC was a cluster randomised controlled clinical
trial with general practices as the unit of randomisation
(Fig. 1). The trial was carried out in the four areas of the
Auvergne region of France, with stratification on each.
The trial is reported according to the extended CON-
SORT statement for cluster randomised trials. The ETIC
was registered with ClinicalTrials.gov (Registration Num-
ber: NCT01065142) [15].
Inclusion and exclusion criteria
Patients aged over 50 years, with New York Heart Asso-
ciation (NYHA) Stage I, II or III HF and with a reduced
or preserved ejection fraction (HFrEF or HFpEF) as
confirmed by the patient’s cardiologist according to the
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European Society of Cardiology guidelines, were eligible
for inclusion [3]. Patients with NYHA Stage I HF were in-
cluded because, even if asymptomatic, they had to manage
the everyday manifestations of disease and might benefit
from patient education; also, it was interesting to know
whether the intervention had an impact on the evolution
of NYHA HF stages. In contrast, the condition of patients
with NYHA Stage IV HF seemed too advanced for edu-
cational sessions to have an impact on their quality of
life, because patients were not included after a hospital
discharge but were included in general practice with
stable CHF. HFrEF was defined as an ejection fraction
of ≤40 %, whereas HFpEF was defined as an ejection
fraction of >40–50 % in combination with signs and/or
symptoms of CHF and evidence of diastolic dysfunction
(abnormal left-ventricular relaxation or diastolic stiff-
ness) [3].
Patients with severe cognitive disorders according to
the GP’s judgement, those institutionalised at the time of
inclusion, those with NYHA Stage IV HF, those partici-
pating in another clinical trial and those lacking French
language skills were excluded.
Instruments and outcomes
The primary outcome was patients’ quality of life, as
measured by the MOS 36-Item Short Form Health Sur-
vey (SF-36), a widely used generic instrument [16], and
the Minnesota Living with Heart Failure Questionnaire
(MLHFQ), an HF-specific instrument, both of which are
considered good psychometric properties [17, 18]. The
SF-36 questionnaire consists of eight dimensions: phys-
ical function, role physical, body pain, general health,
vitality, role emotional, mental health and social func-
tion. The SF-36 physical health score incorporates phys-
ical function, role physical, body pain and general health.
The SF-36 mental health score incorporates vitality, role
emotional, mental health and social function. SF-36
scores range from 0 to 100: 0 indicates the worst quality
of life and 100 the best. MLHFQ score ranges from 0 to
105: 0 indicates best quality of life. Quality of life was
assessed at baseline and at 7, 13 and 19 months using
self-administered questionnaires completed by patients
or their main caregiver within 7 days of their appoint-
ment with the GP. If the patient had literacy difficulties,
the main caregiver interviewed the patient and filled out
the questionnaire.
The secondary outcomes were: all-cause and HF-
associated mortality; all-cause and HF-associated hospi-
talisations and the number of days spent in hospital;
cumulative number of deaths of all causes or HF-
associated hospitalisations and cumulative number of
days of hospitalisation; cumulative number of cases of
acute HF (an acute episode reported by the GP with or
without hospitalisation); cumulative number of visits to
a cardiologist and cumulative number of additional GP
visits (in addition to those dedicated to the trial); adher-
ence to therapy (using a self-administrated questionnaire
at baseline and at the end of follow-up) [19]; evolution
of NYHA HF stage; and changes in weight and body
mass index at 19 months.
Intervention
No medication was tested in this trial and GPs were
allowed to adapt patients’ treatments if necessary. The
GPs in the Intervention Group received a 2-day inter-
active workshop that trained them to deliver a patient
education programme (Table 1). The intervention con-
sisted of patient education on standardised topics: clin-
ical alarm signs, physical activity, diet and cardiovascular
risk factors. The GPs were trained to manage their own
education objectives (e.g. diet, treatment adherence) and
patients’ objectives (e.g. to be able to walk their grand-
children to school). Several patient education sessions
were simulated during the 2-day workshop.
The patients’ education sessions were performed by
their GPs and are detailed in the trial protocol [14]. The
education sessions were standardised in their timing
(every 3 months) and the topics covered. The GPs re-
ceived an education booklet with the topics covered and
education tools (i.e.; Table 2 and Additional file 1: Diet-
ary leaflets and information on clinical alarm signs). The
first educational session (educational diagnosis) for pa-
tients occurred during Month 1 and covered several
topics: lifestyle and dietary habits, physical activity, hob-
bies, leisure activities, projects and details of resources
available to patients (Additional file 2: The educational
diagnosis summary). This first step was necessary to es-
tablish patients’ knowledge, attitude and motivation.
Patients had a further four education sessions, at 4, 7, 10
and 13 months, followed by an overview session at
19 months. The patient education sessions were
adapted to each patient, on the basis of the first edu-
cation session at Month 1 and at each of the following
visits, to match the needs and motivation of each pa-
tient. At the end of each visit, the patients fixed and
agreed their own personal objectives with the GP
(Additional file 3: The education sessions summary).
The healthcare providers had the flexibility to adapt
the programme according to the patients’ experience,
knowledge, needs and desires [20, 21]. Consequently,
education sessions were simultaneously standardised
in their topics and their timing (every 3 months) and
personalised to individual patients. To assess the
quality of the intervention, at the end of each educa-
tion session the GPs reported what they did and the
topics discussed (e.g. clinical alarm signs, physical ac-
tivity, diet, cardiovascular risk factors and adherence;
Additional file 3: The education sessions summary).
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Control
GPs in the Control Group attended a 3-hour informa-
tion session to learn about the case report forms and the
inclusion and exclusion criteria. Their patients had the
same schedule for visits as those in the Intervention
Group but without a specific education intervention (i.e.,
at 1, 4, 7, 10, 13 and 19 months).
Statistical considerations
The sample size estimation and statistical analyses were
presented in Vaillant-Roussel et al. [14]. Sample size esti-
mation was performed to detect a difference of 12 points
for quality of life outcomes (SF-36 and MLHFQ), which
corresponds to an effect size of 0.6, with a statistical
power of 90 % and a two-sided Type 1 error of 5 %, tak-
ing into account clustering by practice (intra-cluster
correlation was considered to be between 0.1 and 0.2)
[13, 16, 17, 22, 23] A 20 % dropout rate was assumed.
On the basis of several simulations, it was estimated that
40 GPs in general practices recruiting five patients each
were required per group, resulting in the recruitment of
200 patients in each group. The statistician was blinded
with regard to treatment allocation.
Statistical analyses were realised in intention to treat
using Stata (version 13; StataCorp LP, College Station,
TX, USA). The main analysis was performed with hier-
archical linear regression models to estimate the effects
of the intervention on SF-36 and MLHFQ scores for the
post-baseline time points adjusted for the baseline score,
as proposed previously [24]. Random effects were used
for practice, individuals within practices and repeated
measurements per individual (slope and intercept). The
results were expressed as the regression coefficient (b)
and 95 % confidence interval (CI). Intra-class correl-
ation coefficients (ICCs) were presented by group. Fi-
nally, a sensitivity analysis was used to investigate the
nature of the missing data and a per-protocol analysis
was also performed.
Results
Recruitment of general practitioners and patients
An overview of the recruitment of GPs and patients is
presented in Fig. 1. Overall, 54 (64 %) of the randomised
GPs were active and enrolled at least one patient into
the trial. The inclusion period lasted 1 year. The GPs re-
cruited 243 patients. Two patients with NYHA Stage IV
HF were excluded from the analysis.
Baseline characteristics of general practitioners and
patients
The characteristics of the active GPs were comparable
between the Intervention and Control Groups (Table 3).
The characteristics of the 241 patients remaining in the
trial are shown in Table 4; 115 patients were included in
Table 1 Training seminar for general practitioners: 2-day workshop
Module 1: Introduction Introduction to the concepts of the Education Thérapeutique des patients Insuffisants Cardiaques
(ETIC; Therapeutic Education for Patients with Cardiac Failure) trial and patient education
Module 2: Heart failure Chronic heart failure: definitions; epidemiology; clinical diagnosis; treatment guidelines;
echocardiographic criteria; cardiac biomarkers—B-type natriuretic peptide (BNP) and NT-
proBNP (how and when to prescribe them)
Clinical symptoms: how to recognise heart failure in daily practice
New York Heart Association (NYHA) stages: definitions; assessment of NYHA stages from case
vignettes
Suspicious clinical signs
Adaptation of physical activity as a function of NYHA stage
Module 3: Concepts of patient education Assessment and building on patients’ existing knowledge
Identification of lifestyle and dietary habits, physical activity, hobbies, leisure activities, projects
and resources available to the patient
Assessment of patients’ stage of change, motivation and attitude
Collaboration with the patient to define achievable and measurable objectives
Module 4: Communication Communication skills
Communication tools
Motivational interviewing
Lifestyle counselling based on the Five As model (ask, assess, advise, assist, and arrange)
Module 5: Role play to simulate a patient
consultation with the general practitioner
Identification and use of patients’ knowledge (clinical alarm signs, physical activity, diet and
cardiovascular risk factors), values, motivation, projects and resources to involve the patient in
their personal objectives
Classification of these personal objectives by therapeutic priority and patient preference
Use of effective communication strategies
Module 6: Case report forms Inclusion and exclusion criteria
How to promote and present the ETIC trial to patients
How to fill in the case report forms
How to organise the follow-up and topics: educational booklet and educational tools (i.e. diet-
ary leaflets, clinical alarm signs)
General practitioners were trained to deliver a patient education programme during a 2-day interactive workshop (six modules)
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the Intervention Group and 126 in the Control Group.
Their mean age was 74 years (± 10.5) and 62 % were
men. HF had been diagnosed between 0 and 35 years pre-
viously and at a median of 5 years earlier (inter-quartile
range = 2–10). There were 101 patients in the Intervention
Group (87.8 %) and 101 patients in the Control Group
(80.2 %) with HF of NYHA Stages II or III (P = 0.11). The
mean left-ventricular ejection fraction was 50.9 % (±
13.2 %) in the Intervention Group and 47.7 % (± 15.2 %)
in the Control Group (P = 0.16). Patients with HFpEF in
the Intervention and Control Group numbered 93
(80.9 %) and 94 (74.6 %), respectively (P = 0.24).
There was no difference between the Intervention and
Control Groups with regard to treatments and patient
adherence (Table 4); 4 % of the patients received no
treatment at baseline. There was no difference in quality
of life scores between the Intervention and Control
Groups when treatment was stratified according to
HFrEF and HFpEF (data not shown). There was no dif-
ference between the two groups with regard to quality of
life (detailed in Table 4). The correlation coefficients of
the MLHFQ and SF-36 physical health scores and the
MLHFQ and SF-36 mental health scores were −0.63
and −0.64, respectively.
Primary outcomes
Quality of life scores are presented in Table 5. The ICC
associated with the MLHFQ primary outcome at
19 months was 0.11. Changes from the baseline were
analysed in the Intervention and Control Groups only
for patients whose data were available at the end of the
trial. The regression coefficient, adjusted for the baseline
results, of the MLHFQ score was b = 1.19 (95 % CI:
−5.94–8.32, P = 0.74). The differences in MLHFQ score
in the Intervention and Control Groups at the 19-month
follow-up were 3 (−4–13) and 1 (−5–13), respectively.
There was no difference in MLHFQ score during follow-
up at 7 and 13 months, respectively: 33.9 (± 29.2) in the
Intervention Group versus 28.3 (± 22.5) in the Control
Group at 7 months, P = 0.14; 33.4 (± 22.1) in the Inter-
vention Group versus 29.5 (± 24.3) in the Control Group
at 13 months, P = 0.22.
The ICC associated with the SF-36 mental and phys-
ical health primary outcome at 19 months was similar
(ICC = 0.01). The regression coefficients, adjusted for the
baseline results, of the SF-36 mental and physical health
scores were b = −1.7 (−7.6–4.15; P = 0.58) and b = 1.6
(−4.03–7.21; P = 0.57), respectively. Differences from the
baseline in SF-36 mental and physical scores between
the Intervention and Control Groups at the 19-month





Gender male, n (%) 17 (63) 20 (74.1)
Age (years), mean (SD) 50.2 (7.9) 51.6 (7.3)
Length of time in practice
(years), mean (SD)
21.9 (7.9) 23.5 (8)
Type of practice, n (%)
Rural 4 (14.8) 3 (11.2)
Suburban 16 (59.3) 12 (44.4)
Urban 7 (25.9) 12 (44.4)
Group practices, n (%) 16 (59.3) 19 (70.4)
Trainee supervisorsan (%) 19 (70.4) 13 (48.2)
Number of patients included,
mean (SD)
4.3 (2) 4.8 (1.8)
aTrainee supervisors were general practitioners (GPs) involved in teaching,
GPs who were university lecturers or those who received students for
internship; SD standard deviation
Table 2 Education intervention topics
Knowledge Do you suffer from heart failure?
Attitudes What is ‘heart failure’ for you?
Motivation What do you know about heart failure?
How do you live with this disease?
What impact has heart failure had on your life (personal,
professional, social)?
What are your fears?
What are your expectations?
Clinical
alarm signs
For you, what could be a clinical alarm sign of your
heart failure?
What should you do to detect clinical alarm signs?




What does physical activity mean for you?
What physical activities do you undertake? Housework?
Leisure (e.g. gardening)? Transportation (e.g. walking, car)?
When are you breathless? (New York Heart Association
assessment)
Regarding your habits, what would you be ready to
change?
Diet Where do you eat your meals?
Who does the cooking?
High-salt food: what do you know about it? How much
do you consume?
What is your point of view and what changes are you
ready to make?
For those with a body mass index ≥30: what are your
diet mistakes (snack food, overeating) or diet troubles?
For those with a body mass index ≤18 (adult patients)
or 21 (elderly patients):
what are your diet mistakes or diet troubles?
The general practitioners received an education booklet covering the
following topics: knowledge/attitudes/motivation; clinical alarm signs; physical
activity; and diet. There was no predetermined order – each theme was
evoked depending on patients’ needs and based on the first
education session
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Table 4 Baseline patient characteristics
Intervention (n = 115) Control (n = 126) P-value
Gender male, n (%) 69 (60) 80 (63.5) 0.58
Age (years), mean (SD) 74.7 (10.3) 73.5 (10.8) 0.42
Chronic heart failure duration, median (IQR) 5 (1–11) 5 (2–10) 0.66
EF mean (SD) 50.9 (13.2) 47.7 (15.2) 0.16
HFpEF n (%) 93 (80.9) 94 (74.6) 0.24
NYHA stage, n (%)
I 14 (12.2) 25 (19.8)
II 69 (60) 67 (53.2) 0.26
III 32 (27.8) 34 (27)
Current smoker, n (%) 14 (12.2) 25 (19.8) 0.11
BMI kg/m2, n (%)a
< 25 25 (22.2) 44 (35.8)
25–30 44 (38.9) 52 (42.3) 0.008
≥ 30 44 (38.9) 27 (21.9)
Hypertension, n (%) 72 (62.6) 65 (51.6) 0.08
Type 2 diabetes, n (%) 30 (26.1) 22 (17.5) 0.10
Hypercholesterolaemia, n (%) 50 (43.5) 54 (42.9) 0.92
COPD, n (%) 9 (7.8) 19 (15.1) 0.08
SF-36 mental health score, mean (SD) 60.3 (21.2) 60.1 (21.3) 0.89
SF-36 physical health score, mean (SD) 52.1 (22.5) 50.9 (22.1) 0.66
MLHFQ score, mean (SD)b 29.1 (22.1) 24.4 (21.7) 0.07
<24 50 (52.6) 64 (57.7)
24–45 22 (23.2) 26 (23.4) 0.64
>45 23 (24.2) 21 (18.9)
Patient adherencec, n (%)
Good adherence 46 (44.2) 49 (43)
Minor nonadherence 56 (53.9) 60 (52.6) 0.67
Nonadherence 2 (1.9) 5 (4.4)
Intervention (n = 102) Control (n = 121) P-value
Treatment, n (%)e 98 (96.1) 117 (96.7) 1.00
β-blocker 63 (61.8) 73 (60.3) 0.83
ACE inhibitor 51 (50) 65 (53.7) 0.58
ARB 34 (33.3) 29 (24) 0.12
ACE inhibitor or ARBd 85 (83.3) 93 (76.9) 0.23
β-blocker and (ACE inhibitor or ARB) 56 (54.9) 60 (49.6) 0.43
Thiazide diuretics 12 (12.6) 16 (13.2) 0.74
Loop diuretics 71 (69.6) 78 (64.5) 0.42
Thiazide diuretics or loop diuretics 76 (74.5) 90 (74.3) 0.98
Mineralocorticoid receptor antagonists 15 (14.7) 21 (17.4) 0.59
Digoxin 11 (10.8) 10 (8.3) 0.52
ACE inhibitor angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, COPD chronic obstructive pulmonary disease, HFpEF heart failure with
preserved ejection fraction, EF ejection fraction, SD standard deviation
an = 5 missing data for body mass index. bQuestionnaires with more than three missing responses were excluded (n= 35: 15 in the Control Group and 20 in the Intervention
Group). cn= 23 missing data for adherence. dOne patient had angiotensin-converting enzyme inhibitor and angiotensin receptor blocker
e18 patients had missing data concerning treatments at baseline
Significant P-value are in bold
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follow-up were: −3.2 (−14.5–4.7) and −0.08 (−13.6–7.5);
and −1 (−8–8) and 0 (−12–10), respectively.
Figure 2 shows the change in quality of life from
baseline to the follow-up period for each SF-36 vari-
able (P = not significant between the Intervention and
Control Groups). A subgroup analysis, based on age
classes, asymptomatic (I) and symptomatic (II and III)
NYHA stages, HFrEF and HFpEF, demonstrated no
significant difference in quality of life scores.
Secondary outcomes
Mortality and healthcare outcomes are detailed in
Table 5. Fifteen deaths occurred in the Control Group
and 10 in the Intervention Group, although this differ-
ence was not statistically significant (P = 0.41). The cu-
mulative number of cases of acute HF was 158/1015
visits (15.6 %; 65/470 for the Intervention Group versus
93/545 for the Control Group, P = 0.16; Table 5 and
Fig. 3). Of all patients with acute HF, 40/158 (25.3 %)
Table 5 End points at Month 19
Intervention (n = 69) Control (n = 82) P-value
Primary outcomes
SF-36 mental health score, mean (SD) 58 (22.1) 58.7 (23.9) 0.57
SF-36 physical health score, mean (SD) 52.8 (23.8) 51.6 (25.5) 0.58
MLHFQ score, mean (SD) 33.4 (22.1) 27.2 (23.3) 0.74
Secondary outcomes
NYHA stage, n (%)a
I 14 (22.6) 21 (29.2)
II 35 (56.5) 34 (47.2) 0.73
III 12 (19.3) 15 (20.8)
IV 1 (1.6) 2 (2.8)
BMI kg/m2, n (%)b
< 25 13 (22) 29 (40.3)
25–30 25 (42.4) 33 (45.8) 0.007
≥ 30 21 (35.6) 10 (13.9)
Patient adherencec, n (%)
Good adherence 23 (37.1) 32 (42.1)
Minor nonadherence 35 (56.5) 42 (55.3) 0.55
Nonadherence 4 (6.4) 2 (2.6)
Mortality, n (%) 10/115 (8.7) 15/126 (11.9) 0.41
Total CHF decompensation/visits (%) 65/470 (13.8) 93/545 (17.1) 0.16
Hospitalisation for CHF decompensation/visits (%) 18/65 (27.7) 22/93 (23.7) 0.57
Hospitalisation not for CHF decompensation/visits (%) 50/470 (10.6) 59/545 (10.8) 0.92
Hospitalisation/visits (%) 62/470 (13.2) 74/545 (13.6) 0.86
Hospitalisation/patients (%) 41/115 (35.7) 54/126 (42.9) 0.26
Total number of days of hospitalisation 1037 867
HF hospitalisation/patients (%) 13/115 (11.3) 17/126 (13.5) 0.61
Death or hospitalisation/patients (%) 45/115 (39.1) 60/126 (47.6) 0.18
Death or HF hospitalisation/patients (%) 20/115 (17.3) 28/126 (22.2) 0.35
dTotal visits related to GP/patients (%) 90/115 (78 %) 106/126(84 %) 0.24
dNumber of GP visits/patient, mean (SD) 8.1 (5.3) 6.4 (4.5) 0.02
Total visits related to cardiologist/patients (%) 85/115 (74 %) 84/126 (67 %) 0.22
Number of cardiologist visits/patient, mean (SD) 3.1 (2.2) 3.1 (2) 0.92
an = 17 missing data for New York Heart Association stage
bn = 20 missing data for body mass index
cn = 13 missing data for adherence
dAdditional general practitioner visits (in addition to those dedicated to the study)
Significant P-value are in bold
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were hospitalised. When patients were hospitalised for
any cause, the cumulative number of days in hospital
was 1037 days in the Intervention Group (median: 8 days
[range: 4–23]) and 867 days in the Control Group (me-
dian: 8 days [range: 3–25]; P = 0.58).
During the 19-month follow-up period, 25/115 (22 %)
patients in the Intervention Group and 20/126 (16 %)
patients in the Control Group had no additional GP
visits (in addition to those dedicated to the trial; P =
0.24). Among patients who consulted their GP, the mean
number of GP visits was 8.1 (± 5.3) in the Intervention
Group and 6.4 (± 4.5) in the Control Group (P = 0.02).
There was no difference in the number of visits to a car-
diologist (Table 5). Figure 4 describes the evolution of
NYHA stages during the follow-up period.
Discussion
Summary of the main results
A pragmatic patient education intervention for HF deliv-
ered by trained GPs did not improve patients’ quality of
life compared with routine care. There was no difference
between the groups in MLHFQ (P = 0.74), SF-36 mental
health (P = 0.57) or SF-36 physical health (P = 0.58)
questionnaire scores at the 19-month follow-up examin-
ation. The ICC associated with MLHFQ score was 0.11
and those associated with the SF-36 mental and physical
health scores were similar (ICC = 0.01).
Meaning of the findings
Although this trial did not detect any impact on the pri-
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Fig. 2 Changes in quality of life from baseline to the follow-up period for each Short Form 36 variable. IG, Intervention Group; CG, Control Group; Short
form 36 physical health variables: PF, physical function; RP, role physical; BP, body pain; GH, general health. Short form 36 mental health variables: VT, vitality;
RE, role emotional; MH, mental health; SF, social function. Short Form 36 variables are described at baseline (M0) and at 7, 13 and 19 months
(M7, M13 and M19)
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from patients enrolled, treated and followed-up in pri-
mary care [7–10]. In Europe, most published studies on
patient education programmes involve hospitalised pa-
tients or patients discharged from hospital. The profiles
of these patients differ from those treated in primary
care, which comprise a population with stable HF, as in
the ETIC, composed of elderly patients with a relatively
good quality of life [12, 25]. The characteristics of
patients with HF enrolled in the ETIC more closely re-
semble those of patients enrolled in the French IM-
PROVEMENT study on primary care, where the mean
patient age was 73 years and 40 % of patients were
female [26]. Many published studies include only pa-
tients with HFrEF [12], younger patients [7, 9], or pre-
dominantly male patients [8, 11]. Consequently, most
data published to date relate to patients with HFrEF
[27]. The ETIC chose a pragmatic design and included a
broad range of patients with CHF, most of whom had
HFpEF, because we deliberately chose not focus on just
one segment of the CHF population [27]. In the IM-
PROVEMENT study, only 51 % of patients with an
echocardiogram exhibited left-ventricular systolic dys-
function (poorly contracting left ventricle, enlarged left
ventricle or ejection fraction under 40 %) [26].
The quality of life of the patients was measured using
two questionnaires, the MLHFQ and the SF-36, because
the first is specific and the second is generic. The sample
size was estimated by taking into account an anticipated
ICC of between 0.1 and 0.2 [22]. According to the ICC
results, the data were more dispersed for MLHFQ score
(ICC = 0.11) than SF-36 scores (mental SF-36 and phys-
ical SF-36 ICC = 0.01), which indicates that, in this con-
text, the MLHFQ is probably more discriminative.
These results could be useful for future studies in simi-
lar settings.
The quality of life scores at the end of follow-up at
19 months appeared surprisingly stable in the elderly
patients enrolled in the ETIC study, especially the SF-
36 physical health score, reflecting the natural pro-
gression of health-related quality of life in general
population [28]. We cannot attribute this to an effect
of our education sessions, because this stability in
quality of life was found in both groups. We propose
that the act of participating in a study stabilised pa-
tients’ quality of life (an example of the Hawthorne
effect). The same stability was found in another study
involving patients with stable CHF conducted in pri-
mary care in Germany [12].
We compared the number of additional GP consultations
for all patients and observed no difference between the
Intervention and Control Groups. However, among pa-
tients who consulted their GP, the mean number of consul-
tations was significantly higher in the Intervention Group.
This was not the case for visits to the cardiologist. These
results are consistent with another study in the primary
care setting [12].
Strengths and limitations of the trial
The ETIC was one of the largest trials in the primary
care setting to study the effects of an educational inter-
vention on patients with CHF. A cluster design was
chosen for pragmatic reasons and to avoid contamin-
ation bias.
Reviews of studies on management programmes for
patients with HF have shown mixed effects on hospital
admissions, mortality and quality of life [29, 30]. There
was large variability in the complexity of case manage-
ment, patient education, training of care managers and
care settings. Overall positive effects on predominantly
disease-specific quality of life were found in a short-term
follow-up but the results observed during longer follow-
ups were largely non significant. Short-term positive ef-
fects on quality of life were observed in hospitalised
patients and those with acute HF, who exhibited low
baseline scores, enabling short-term effects to be de-
tected in comparison with controls [7, 10]. The potential
for improving the quality of life of patients recovering
from hospitalisation may be higher than that of patients
with stable disease treated in primary care [13]. The
ETIC trial included patients with stable HF with rela-
tively high baseline quality of life scores; perhaps it was
unrealistic to attempt to improve the quality of life of
this population, even if the follow-up period (19 months)
was longer than in other studies.
The aim of this trial was a change of 12 points in the
quality of life scores, to show not only a statistically
significant but also a clinically relevant difference [31].
Although some studies tried to find a difference of five
points in quality of life scores, others chose a difference
of 12 points for the same reasons [12, 13, 32]. However,
this difference cannot explain the absence of an effect. It
is also the case for the power, because even if a differ-
ence of five points had been chosen, this study would
not show a significant difference (Table 5).
Finally, the intensity of the intervention delivered by
the GPs may have been too low and other factors out-
side the disease-related intervention may have had a
greater impact on quality of life. Quality of life is a
multifactorial measure that may be too complex to be
changed solely by GPs trained in patient education.
Consequently, even if quality of life is a good clinical in-
dicator of health status, it is probably difficult to show
a significant improvement as the result of an interven-
tion in an elderly population with stable HF. Rather,
utilisation of healthcare and treatment optimisation or
self-care behaviour may be more effective, measurable
outcomes [12, 32–34].
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The number of participants per site may seem inad-
equate but we sought the best balance between the num-
ber of GPs and the number of patients enrolled by each
GP based on the capacity for inclusion and feasibility in
terms of the workload (including the follow-up). Another
team in Germany estimated the same capacity for inclu-
sion per GP [12]. Finally, it is important to note that each
active GP contributed 4.3 (± 2) patients to the Control
Group and 4.8 (± 1.8) patients to the Intervention Group
whereas, according to the study design, the number of pa-
tients to be included in each group should have been five.
The limitations of this trial include a dropout rate of
36 % after randomisation among GPs, either because
they withdrew consent to participate (31 %) or failed to
recruit patients (5 %). Although the recruitment goal
was not reached, the lack of significant difference be-
tween the randomised groups cannot be attributed to a
lack of power: the effect size for the primary outcome
was minimal (less than 0.27 [−0.07–0.61]) and the ICC
was lower than expected, meaning that the sample size
could have been smaller. In France, clinical research by
GPs in primary care is still relatively new and this is one
possible explanation for the high dropout rate [35].
Another explanation could be that GPs who agreed to
participate but ultimately did not found the trial work-
load to be too heavy. The generalisability of the data
from the remaining GPs who participated in the ETIC
trial can be considered good, because they are very simi-
lar to the national characteristics of GPs as assessed in
2009 [36]. Furthermore, the characteristics of the pa-
tients included were similar to those of patients with
CHF in France in primary care [26].
At baseline, the patients’ characteristics were similar,
except that those in the Intervention Group were more
likely to be overweight or obese compared with those in
the Control Group. The same difference was found at
the end of follow-up. The patients had a similar quality
of life according to the SF-36 but, although without stat-
istical significance, MLHFQ scores were worse in the
Intervention Group (P = 0.07). One possible explanation
is that selection bias was present: the training received
by the GPs in the Intervention Group may have made
them feel more competent and, therefore, they may have
included more severely ill patients in the trial. To avoid
this bias, we could have randomised the GPs after they
had recruited their patients, using Zelen’s method [37].
However, this option was not feasible because of the
short life expectancy of the patients: we considered the
mean age of patients at the time of inclusion to be high,
at 74 years. It was inadvisable to recruit patients over a
period longer than 1 year and then randomise the GPs
to receive training.
As the ETIC population was a population with a good
quality of life and with a significant proportion of patients
with HFpEF, our results could not be extrapolated to pa-
tients with HFrEF and a poor quality of life. Most of the
patients in our study had HFpEF and, as treatment is not
conclusively known to be of benefit in such patients, we
hypothesise that it is the same with patient education.
However, when outcomes were stratified according to
HFrEF and HFpEF, the type of HF had no influence. We
failed to demonstrate an impact of our intervention re-
gardless of the type of HF.
To assess the quality of the intervention, at the end of
each education session the GPs reported what they did
and the topics discussed [14]. However, we cannot make
any inferences on the intensity of the intervention deliv-
ered by the GPs in the Intervention Group. It is possible
that a 2-day workshop is insufficient to teach GPs how
to conduct successful counselling of HF patients regard-
ing lifestyle. However, a longer workshop may be unreal-
istic for GPs and would not equate to a pragmatic
design suitable for everyday practice. Finally, we cannot
exclude the possibility that we were unable to observe
an effect of the intervention because of the inclusion of
motivated GPs with a special interest in the topic in
both trial arms.
Conclusion
Patient education delivered by GPs to elderly patients
with stable CHF in the ETIC programme did not achieve
an improvement in their quality of life compared with
routine care. Further research on improving the quality
of life and clinical outcomes of elderly patients with HF
in primary care is necessary.
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